載入...
Preliminary safety, pharmacokinetics, and efficacy of regorafenib, cisplatin, and pemetrexed in patients with advanced non-squamous non-small cell lung cancers
PURPOSE: The addition of bevacizumab, an anti-angiogenesis agent, to cytotoxic chemotherapy improves survival in patients with advanced non-squamous non-small cell lung cancers (nsNSCLCs). Regorafenib is an oral multi-targeted kinase inhibitor with potent anti-angiogenic activity that is approved fo...
Na minha lista:
| 發表在: | Clin Lung Cancer |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4750397/ https://ncbi.nlm.nih.gov/pubmed/26003007 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2015.04.003 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|